NKT3964, a novel oral CDK2 degrader, is currently undergoing a Phase 1 clinical trial aimed at evaluating its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in adults with advanced or metastatic solid tumors. The trial's focus on specific cancer types, particularly those with CCNE1 amplification, positions it strategically within a niche market that includes hard-to-treat cancers such as triple-negative breast cancer and advanced ovarian cancer. The competitive landscape includes existing CDK inhibitors and emerging protein degraders, necessitating a robust differentiation strategy based on clinical efficacy and safety profiles. Successful outcomes could lead to a significant market opportunity, particularly in the context of unmet medical needs in oncology. Diligence should focus on regulatory pathways, potential partnerships for development, and the evolving landscape of targeted therapies.